Concord Biotech

42
Sell
  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE338H01029
  • NSEID: CONCORDBIO
  • BSEID: 543960
INR
548.40
-7.8 (-1.4%)
BSENSE

Nov 20

BSE+NSE Vol: 1.38 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Consolidated - Profit And Loss Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'20
No of Months
12
12
12
12
12
12
Operating Income
1,054.00
1,200.00
1,016.00
853.00
712.00
512.00
Less :Inter divisional transfers
0.00
0.00
0.00
0.00
0.00
0.00
Less: Excise
0.00
0.00
0.00
0.00
0.00
0.00
Net Sales
1,054.00
1,200.00
1,016.00
853.00
712.00
512.00
Expenditure (Ex Depriciation)
Stock Adjustments
-71.00
-14.00
-12.00
-15.00
-23.00
-4.00
Raw Materials Consumed
316.00
320.00
241.00
195.00
187.00
134.00
Power & Fuel Cost
116.00
112.00
104.00
97.00
71.00
37.00
Employee Cost
176.00
138.00
123.00
110.00
95.00
62.00
Operating Expenses
30.00
26.00
27.00
24.00
17.00
30.00
General and Administration Expenses
-1.00
-1.00
-1.00
-1.00
-1.00
-1.00
Selling and Distribution Expenses
33.00
34.00
33.00
23.00
21.00
15.00
Cost of Software developments
0.00
0.00
0.00
0.00
0.00
0.00
Miscellaneous Expenses
14.00
11.00
8.00
13.00
22.00
15.00
Expenses Capitalised
0.00
0.00
0.00
0.00
0.00
0.00
Total Expenditure
686.00
693.00
584.00
509.00
439.00
307.00
Operating Profit (PBDIT) excl Other Income
367.00
506.00
432.00
343.00
273.00
204.00
Other Income
52.00
44.00
33.00
35.00
23.00
31.00
Operating Profit (PBDIT)
420.00
551.00
465.00
379.00
297.00
235.00
Interest
0.00
1.00
3.00
5.00
6.00
1.00
Profit before Depriciation and Tax
419.00
550.00
462.00
374.00
291.00
234.00
Depreciation
74.00
54.00
53.00
54.00
50.00
21.00
Profit Before Taxation & Exceptional Items
345.00
495.00
409.00
320.00
241.00
213.00
Exceptional Income / Expenses
0.00
0.00
0.00
0.00
0.00
0.00
Profit Before Tax
344.00
494.00
412.00
322.00
237.00
213.00
Provision for Tax
85.00
122.00
104.00
81.00
62.00
44.00
Profit After Tax
256.00
372.00
304.00
238.00
178.00
168.00
Extraordinary Items
0.00
0.00
0.00
0.00
0.00
0.00
Adj to Profit After Tax
0.00
0.00
0.00
0.00
0.00
0.00
Profit Balance B/F
1,691.00
1,404.00
1,168.00
981.00
877.00
560.00
Profit Available for appropriations
1,951.00
1,776.00
1,476.00
1,221.00
1,052.00
729.00
Appropriations
1,951.00
1,776.00
1,476.00
1,221.00
1,052.00
729.00
Equity Dividend (%)
755.00%
875.00%
875.00%
683.00%
51.20%
392.50%
Earnings Per Share
24.78
35.52
29.45
22.95
16.72
177.82
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2026 is -12.10% vs 18.01% in Mar 2025

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2026 is -27.41% vs 17.27% in Mar 2025

stock-summary

Interest

YoY Growth in year ended Mar 2026 is -20.96% vs -67.28% in Mar 2025

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2026 is -31.27% vs 22.39% in Mar 2025

Compare Profit and Loss Results of Concord Biotech
Markets Mojo
Figures in Cr
consolidated - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
1,054.00
2,950.00
-1,896.00
-64.27%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
1,054.00
2,950.00
-1,896.00
-64.27%
Expenditure (Ex Depriciation)
Stock Adjustments
-71.00
-136.00
65.00
47.79%
Raw Materials Consumed
316.00
1,413.00
-1,097.00
-77.64%
Power & Fuel Cost
116.00
54.00
62.00
114.81%
Employee Cost
176.00
420.00
-244.00
-58.10%
Operating Expenses
30.00
155.00
-125.00
-80.65%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
33.00
260.00
-227.00
-87.31%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
14.00
71.00
-57.00
-80.28%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
686.00
2,350.00
-1,664.00
-70.81%
Operating Profit (PBDIT) excl Other Income
367.00
600.00
-233.00
-38.83%
Other Income
52.00
82.00
-30.00
-36.59%
Operating Profit (PBDIT)
420.00
683.00
-263.00
-38.51%
Interest
0.00
24.00
-24.00
-100.00%
Profit before Depriciation and Tax
419.00
659.00
-240.00
-36.42%
Depreciation
74.00
98.00
-24.00
-24.49%
Profit Before Taxation & Exceptional Items
345.00
560.00
-215.00
-38.39%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
344.00
560.00
-216.00
-38.57%
Provision for Tax
85.00
140.00
-55.00
-39.29%
Profit After Tax
256.00
420.00
-164.00
-39.05%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
1,691.00
1,422.00
269.00
18.92%
Profit Available for appropriations
1,951.00
1,839.00
112.00
6.09%
Appropriations
1,951.00
1,839.00
112.00
6.09%
Equity Dividend (%)
755%
90%
665.00
Earnings Per Share
24.78
9.22
15.56
168.76%
Profit And Loss - Net Sales
Net Sales 1,054.89 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -12.10% vs 18.01% in Mar 2025

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) 367.94 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -27.41% vs 17.27% in Mar 2025

Profit And Loss - Interest
Interest 0.82 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -20.96% vs -67.28% in Mar 2025

Profit And Loss - Profit After Tax
Profit After Tax 256.32 Cr
in Mar 2026

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2026 is -31.27% vs 22.39% in Mar 2025